ABL1 and neoplasm: In a research work (Fig. 3), H. Liang et al. developed a liposome-encapsulated with a hydrophobic drug (CHMFL-ABL-053) NCs (NC@Lipo), delivering them to the specific tumor location with high loading efficacy.79 CHMFL-ABL-053 is a selective BCR-ABL inhibitor for chronic myeloid leukemia, demonstrate poor water solubility, and reduced bioavailability.